We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biodiagnostics System Tests Patients for Different Disease Targets

By LabMedica International staff writers
Posted on 29 Jun 2009
A biodiagnostic system simultaneously tests patients for different disease targets, on-site in a laboratory, community hospital, or in a doctor's office, in less than an hour.

The nanoparticle-based system can detect very low concentrations of molecules associated with disease; a technology that has the potential to transform the future of medical diagnostics and patient point-of-care.

Chad Mirkin, Ph.D., the George B. More...
Rathmann professor of chemistry and director of the International Institute for Nanotechnology at Northwestern University (Evanston, IL, USA) invented the nanoparticle-based diagnostic system that can detect very low concentrations of molecules associated with disease.

Nanosphere commercialized many of the nanoparticle-based, medical diagnostic assays built upon the principles of Dr. Mirkin's inventions. This led to the development of the Verigene Id system. The platform enables simple, cost-effective, and highly sensitive genomic and proteomic testing on a single platform.

The Lemelson-Massachusetts Institute of Technology (MIT; Cambridge, MA, USA) US$500,000 prize was awarded to Dr. Mirkin, cofounder and member of the board of directors of Nanosphere and NanoInk, companies that develop and commercialize advanced molecular diagnostics systems. The Lemelson-MIT Prize recognizes individuals who transform their ideas into inventions and innovations that improve the world. The prize was awarded on June 25, 2009 at MIT.

When Dr. Mirkin received the award he commented, "The world doesn't want just another way. It wants a better way."

Related Links:
The Lemelson-Massachusetts Institute of Technology Program
International Institute for Nanotechnology at Northwestern University



New
Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
New
Clinical Informatics Platform
CLARION™
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Microbiology

view channel
Image: The findings suggest that people with mpox can transmit the virus even without clinical symptoms (image credit: Adobe Stock)

Study Finds Hidden Mpox Infections May Drive Ongoing Spread

Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.